Allegro NV, a biomedical company developing transformative nanotechnology-based treatments for degenerative joint disease, today presented positive preclinical data demonstrating the satisfactory ...

About NDV-01 NDV-01 is an investigational, innovative sustained-release formulation of two complementary, well-established, chemotherapy agents, gemcitabine and docetaxel (gem/doce). It is designed ...

A team of nurses created a standardized patient handoff process that improved communications between nurses and with patients.

Lead investigational program, NDV-01, for High-Grade Non-Muscle Invasive Bladder Cancer, is being evaluated in a Phase 2 study. In addition, preparations are underway to advance sepranolone, a Phase ...

Misdiagnosis is a relatively common issue that physicians must be vigilant against, according to a presenter at ACP Internal ...

Eisai/Biogen’s Leqembi (lecanemab) was fully approved in the US in July 2023, and Eli Lilly’s Kisunla (donanemab) in July ...

The Phase 4 ENABLE study is set to be first in the U.S. to collect real-world safety and efficacy data of Briumvi for ...

Dana-Farber Cancer Institute nurse scientists and clinicians are presenting key studies at the 50th annual Oncology Nursing ...

The FDA granted a positive review for an acute myeloid leukemia drug trial, with initial dosing expected in 2025.

Three state-funded residential treatment facilities serving children and teens with serious mental health challenges could ...

Cogent Biosciences, Inc. topline results for phase 2/3 studies on bezuclastinib targeting systemic mastocytosis & GIST are ...